REGENXBIO Announces $39M Settlement With Sarepta Resolving All Elevidys Patent Litigation

REGENXBIO has announced a $39 million settlement with Sarepta Therapeutics, resolving all patent litigation related to the Elevidys gene therapy. This settlement aims to eliminate ongoing legal disputes and allows both companies to focus on their respective business strategies. The resolution may have implications for REGENXBIO's future operations and market position.